行情

AMPE

AMPE

Ampio制药
AMEX

实时行情|Nasdaq Last Sale

0.3990
+0.0226
+6.00%
盘后: 0.4000 +0.001 +0.25% 17:06 12/13 EST
开盘
0.4000
昨收
0.3764
最高
0.4000
最低
0.3800
成交量
47.64万
成交额
--
52周最高
1.310
52周最低
0.2600
市值
6,329.93万
市盈率(TTM)
-9.2361
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AMPE 新闻

  • Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number
  • PR Newswire.12/04 13:30
  • Ampio execs subpoenaed over alleged insider trading
  • Seeking Alpha - Article.11/07 21:57
  • Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility
  • PR Newswire.10/10 13:30
  • Ampio Pharma Offers Update On Continued Progress Of AP-013 Phase 3 Trial, Manufacturing Facility
  • Benzinga.10/10 12:35

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

AMPE 简况

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
展开

Webull提供Ampio Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。